Newborn screening tests for a variety of conditions are available in every state, however, test performance and response rate by each state is very different. Mayo Clinic’s Biochemical Genetics Laboratory created the Collaborative Laboratory Integrated Reports tool to mitigate the national (and international) problem of false positives and to raise the bar on test performance.
Wednesday, August 9 | 11 a.m.–noon CT
An educational overview of the large category of peripheral neuropathies, discussing various testing platforms strengths and weaknesses, with a focus on identifying hereditary neuropathies.
Wednesday, August 30 | Noon–1 p.m. CT
This presentation offers an educational overview of next-generation sequencing (NGS) testing for hematologic malignancies, specifically myeloid disorders and multiple myeloma.
Originally Presented June 12, 2017
This presentation offers an educational overview of autoimmune central nervous system disorders, evaluations (including antibody testing), and treatments.
Mayo Clinic has launched a first-of-its-kind clinical test that will be used to help patients who may be at a diagnostic “dead end” with other genetic testing. The mate-pair sequencing test can identify chromosome alterations or “breakpoints” involved in chromosome rearrangements, pinpointing the precise genes involved.
Clinical Laboratory News recently highlighted a Mayo Clinic study that shows how plasma ceramides may predict cardiovascular events in patients with or without coronary artery disease.